Russ Conroy

Findings from the phase 3 DAWNA-2 trial suggest that dalpiciclib plus endocrine therapy may be a potential novel first-line treatment option for hormone receptor–positive, HER2-negative advanced breast cancer.

Data from the phase 3 FRESCO and FRESCO-2 trials support the new drug application for fruquintinib as a treatment for patients with previously treated metastatic colorectal cancer.

Patients with nonsquamous non–small cell lung cancer experiencing clinical benefit with sitravatinib plus nivolumab in the phase 3 SAPPHIRE trial are eligible to remain on treatment.

Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy.

Supporting data for the supplemental new drug application for toripalimab plus chemotherapy in recurrent metastatic triple-negative breast cancer come from the phase 3 TORCHLIGHT study.

Investigators plan to initiate a phase 2 study evaluating AFM13 plus AB-101 in patients with relapsed/refractory classical Hodgkin lymphoma in the first half of 2024.

Mitazalimab is currently under investigation in combination with chemotherapy as a treatment for patients with metastatic pancreatic ductal adenocarcinoma in the phase 2 OPTIMIZE-1 trial.

Asciminib does not appear to interfere with the general life activities of patients with resistant/intolerant chronic phase chronic myeloid leukemia in the phase 3 ASCEMBL trial.

Hospitalization rates appear to be comparable between patients receiving trastuzumab deruxtecan and trastuzumab emtansine for HER2-positive breast cancer in the phase 3 DESTINY-Breast03 study.

Investigators say that they do not have any safety concerns regarding GEN-001 and avelumab in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Adult patients with indolent systemic mastocytosis can now receive avapritinib following the FDA’s approval of the agent.

Findings from a retrospective analysis highlight no significant differences in metastasis-free survival in patients with muscle-invasive bladder cancer who received radical cystectomy vs trimodality therapy.

Santosh Rao, MD, discusses ongoing and potential future research efforts aiming to maximize the benefits that patients with kidney cancer may derive from integrative oncology treatment techniques.

Santosh Rao, MD, discusses guideline recommendations and therapeutic techniques that underscore the current integrative oncology landscape for patients with kidney cancer.

Patients with relapsed/refractory diffuse large B-cell lymphoma can now receive epcoritamab following the FDA’s approval of the agent.

The addition of cabozantinib to nivolumab and ipilimumab also appears to improve responses in patients with advanced renal cell carcinoma in the phase 3 COSMIC-313 trial.

Safety findings from the phase 3 FLAURA2 trial appear to be consistent with the known profiles of osimertinib and chemotherapy for the treatment of those with EGFR-mutated non–small cell lung cancer.

Investigators are expected to share initial safety and efficacy data from a phase 1/2 trial assessing IMPT-314 as a treatment for aggressive B-cell lymphoma in the second half of 2023.

Prexasertib is currently under investigation as part of a phase 2 trial as a treatment for patients with platinum-resistant ovarian cancer, endometrial adenocarcinoma, and urothelial cancers.

The FDA requests additional information requiring time and resources extending beyond the current evaluation period for vic-trastuzumab duocarmazine in advanced HER2-positive breast cancer.

Findings from a phase 2 trial suggest that trabectedin plus radiotherapy is a tolerable treatment option in patients with myxoid liposarcoma despite yielding an unsatisfactory overall response rate.

Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.

Although findings from a population-based meta-analysis suggest a greater risk of death in patients due to cancers diagnosed during pregnancy and postpartum, not all disease sites had the same risk.

The FDA requests additional data and a safety update regarding N-803 plus BCG as a treatment for patients with BCG-unresponsive non-muscle invasive bladder carcinoma.

Findings from a nested case-control study may enable individualized colorectal cancer risk estimations for Hodgkin lymphoma survivors who receive radiotherapy plus procarbazine.

China’s National Medical Products Administration has also approved zanubrutinib as a treatment for patients with Waldenström macroglobulinemia based on findings from the phase 3 ASPEN trial.

Findings from the phase 3 ORIENT-31 trial support the use of sintilimab plus chemotherapy as a potential novel treatment strategy for those with EGFR-mutated nonsquamous non–small cell lung cancer.

Investigators will assess INB-400 as a treatment for patients with newly diagnosed glioblastoma in a phase 2 trial expected to initiate in the second half of 2023.

Treatment with isolated hepatic perfusion appears to yield improved progression-free survival compared with best alternative care in patients with isolated uveal melanoma liver metastases.

An ancillary analysis of 2 clinical trials finds that pathologic complete response may be a prognostic factor of clinical outcomes in soft tissue sarcoma in future studies.